Sandoz, Momenta See Huge Generic Lovenox Sales at Sanofi's Expense

摘要

Initial sales figures from Sandoz and Momenta Pharmaceuticals show their generic version of Sanofi-Aventis' blood thinner Lovenox has already taken away significant market share from Sanofi.rnIn its first nine weeks on the market, generic Lovenox (enoxaparin sodium) brought in about $292 million in sales and managed to capture more than half of the brand drug's market share, Jon Symonds, chief financial officer for Novartis, which owns Sandoz, said last month.